CD274 and triple-negative breast carcinoma: Two agents have been approved as first line therapy in combination with chemotherapy for patients with PD-L1 + unresectable locally advanced and metastatic triple-negative breast cancer (TNBC): Atezolizumab, an antibody against PD-L1, and pembrolizumab, an antibody against anti-PD-1 [2–5].